Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 2(2)
Phase 1(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06794372Phase 2Recruiting

[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

Role: lead

NCT05499637Phase 2Recruiting

[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Role: lead

NCT05420727Phase 1Completed

Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach

Role: lead

NCT04663126Early Phase 1Terminated

Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma

Role: lead

All 4 trials loaded